Becton Dickinson Change in Inventories 2010-2025 | BDX
Becton Dickinson annual/quarterly change in inventories history and growth rate from 2010 to 2025. Change in inventories can be defined as the increase or decrease in a company's inventories for the period.
- Becton Dickinson change in inventories for the quarter ending June 30, 2025 was $0M, a 0% increase year-over-year.
- Becton Dickinson change in inventories for the twelve months ending June 30, 2025 was $98M, a 753.33% decline year-over-year.
- Becton Dickinson annual change in inventories for 2024 was $0.098B, a 753.33% decline from 2023.
- Becton Dickinson annual change in inventories for 2023 was $-0.015B, a 97.62% decline from 2022.
- Becton Dickinson annual change in inventories for 2022 was $-0.631B, a 660.24% increase from 2021.
Becton Dickinson Annual Change in Inventories
(Millions of US $) |
| 2024 |
$98 |
| 2023 |
$-15 |
| 2022 |
$-631 |
| 2021 |
$-83 |
| 2020 |
$-120 |
| 2019 |
$-149 |
| 2018 |
$246 |
| 2017 |
$-46 |
| 2016 |
$69 |
| 2015 |
$200 |
| 2014 |
$-189 |
| 2013 |
$-145 |
| 2012 |
$-92 |
| 2011 |
$-117 |
| 2010 |
$-117 |
| 2009 |
$-91 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$57.228B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
